Loading...
Market
What will be the outcome of Brenus Pharma's Phase I clinical trials by December 31, 2024?
3
Resolution / Starting Odds
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Official announcement from Brenus Pharma or clinical trial registries
Story
Brenus Pharma Secures €22.2M ($25M) to Accelerate Cancer Vaccine Trials
Sep 18, 2024, 07:37 AM
Brenus Pharma, a Lyon-based biotech company specializing in the development of precision cancer vaccines, has successfully raised €22.2 million ($25 million) in a Series A funding round. The financing was led by Angelor and will be used to accelerate clinical trials of its cancer vaccines. This significant investment underscores the growing interest and support for innovative cancer treatment solutions in the biotech sector.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Yes • 50%
No • 50%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Yes • 50%
No • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%